Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. is poised for significant financial growth, evidenced by a projected increase in adjusted operating margin from 25.4% in 2024 to 29.7% by 2028, alongside anticipated operating cash flow exceeding $630 million from 2025 to 2028. The company demonstrated resilience with fourth-quarter results reflecting consecutive top and bottom-line growth, and has adjusted its FY 2025 revenue estimate upward to $269.5 million, aligning with the new guidance range. Furthermore, the launch of exclusive generic products and a rising demand in the ACTH gel market are contributing to a strong outlook, signaling an optimistic growth trajectory moving into 2025.

Bears say

ANI Pharmaceuticals has experienced significant revenue declines in its Brands segment during the second and third quarters of 2024 due to shifting market conditions for certain products, particularly Cortrophin, which has encountered recurring pricing pressures during the first quarter. Management has acknowledged ongoing challenges, including decreased market access linked to inadequate funding from non-profit foundations for Medicare co-pays in 2025, which may further hinder revenue stability. Although recent quarterly results reflected total revenue exceeding expectations, the forecast indicates a substantial anticipated drop in revenues for the first quarter of 2025, raising concerns about long-term performance and sustainability in the face of these ongoing market issues.

ANI Pharma (ANIP) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 13 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.